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Objective: Bone morphogenic protein (BMP)-2 is approved for fracture non-union and spine fusion. We
aimed to further dissect its downstream signaling events in chondrocytes with the ultimate goal to
develop novel therapeutics that can mimic BMP-2 effect but have less complications.
Methods: BMP-2 effect on cyclooxygenase (COX)-2 expression was examined using Real time quantitative
PCR (RT-PCR) and Western blot analysis. Genetic approach was used to identify the signaling pathway
mediating the BMP-2 effect. Similarly, the pathway transducing the PGE2 effect on ATF4 was investigated.
Immunoprecipitation (IP) was performed to assess the complex formation after PGE2 binding.
Results: BMP-2 increased COX-2 expression in primary mouse costosternal chondrocytes (PMCSC). The
results from the C9 Tet-off system demonstrated that endogenous BMP-2 also upregulated COX-2
expression. Genetic approaches using PMCSC from ALK2fx/fx, ALK3fx/fx, ALK6/, and Smad1fx/fx mice
established that BMP-2 regulated COX-2 through activation of ALK3eSmad1 signaling. PGE-2 EIA showed
that BMP-2 increased PGE2 production in PMCSC. ATF4 is a transcription factor that regulates bone
formation. While PGE2 did not have signiﬁcant effect on ATF4 expression, it induced ATF4 phosphory-
lation. In addition to stimulating COX-2 expression, BMP-2 also induced phosphorylation of ATF4. Using
COX-2 deﬁcient chondrocytes, we demonstrated that the BMP-2 effect on ATF4 was COX-2-dependent.
Tibial fracture samples from COX-2/ mice showed reduced phospho-ATF4 immunoreactivity compared
to wild type (WT) ones. PGE2 mediated ATF4 phosphorylation involved signaling primarily through the
EP2 and EP4 receptors and PGE2 induced an EP4-ERK1/2-RSK2 complex formation.
Conclusions: BMP-2 regulates COX-2 expression through ALK3eSmad1 signaling, and PGE2 induces ATF4
phosphorylation via EP4-ERK1/2-RSK2 axis.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.COX, Cyclooxygenase; ATF,
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Bone morphogenic protein (BMP)-2 regulates cellular function
by binding serine/threonine kinase receptors composed of a com-
plex of type I and type II receptors with subsequent phosphoryla-
tion/activation of Smad1/5/8. Three different type I BMP receptors
(ALKs2, 3, and 6) have been identiﬁed1,2. Recombinant BMP-2 is
FDA approved to stimulate bone formation in spine fusion surgery
and for the treatment of non-union of tibial fractures3,4. Recent
clinical reports have documented adverse events related to the use
of BMP-2 that include ectopic bone formation, osteolysis and soft
tissue inﬂammation5e7. More clearly deﬁning the downstreamublished by Elsevier Ltd. All rights reserved.
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as well as lead to the development of more selective agents for
skeletal diseases.
A classic Smad signaling pathway mediates BMP-2 receptor
signaling. Smads 1, 5 and 8 associate with the type I receptors and
are phosphorylated and released into the cytoplasm following
ligand binding to the receptor. The receptor associated Smads form
a complex with Smad4 in the cytoplasm, and then translocate to
the nucleus and modulate gene transcription. In addition, BMP
receptors also activate the mitogen activated protein kinase
(MAPK) signaling pathway. TAK1 is a MAP-kinase-kinase-kinase
that associates with the receptor complex and initiates signaling
through the MAPK pathways. Recent reports show that TAK1 is an
important mediator of BMP-2 effects in chondrocytes8e10. We have
also shown that the classic Smad and a non-classic TAK1-p38-ATF2
pathways are both involved in maintenance of articular cartilage
and have a role in the pathogenesis of osteoarthritis (OA)11.
In addition to its effect on osteochondral speciﬁc transcriptional
factors, BMP-2 also increases the expression of cyclooxygenase
(COX)-2 in osteoblasts12. COX-2 is a critical factor in the skeletal
repair process as COX-2 deletion mutant (COX-2/) mice have
delayed fracture union13. PGE2 is a major metabolite downstream
of COX-2. PGE2 exerts its effect through binding to G-protein
coupled cell receptors, EP1, EP2, EP3, and EP414. Our previous study
indicates that PGE2 inhibits the differentiation of chicken growth
plate chondrocytes15. However, the reports from other groups
demonstrate a complex interaction of BMP-2 and COX-2. PGE2 can
upregulate BMP-2 expression in human mesenchymal stem cells
via its EP4 receptor16,17. We also previously demonstrate that sys-
temic administration of EP4 agonist accelerates fracture healing in
COX-2/ mice18. The ﬁndings from other groups have shown that
both EP2 and EP4 agonists enhance fracture healing19,20. In
contrast, our previous study demonstrates that EP1 receptor is a
negative regulator of fracture healing21.
The EP4 receptor has a unique long intracellular domain that can
be internalized upon ligand binding and forms complex in cyto-
plasm with other molecules22. For examples, PGE2 can activate
ERK1/2 pathway through EP4 and induce ATF4 phosphorylation in
cancer cells23,24. Previous studies have established that ERK1/2 can
phosphorylate and activate RSK-225. ATF4 plays a critical role in
skeletal development and maintenance. ATF4 null mutant mice
exhibit an osteoporotic phenotype due to a reduced bone formation
rate. Enzymatic activity assay revealed that a 90KD ribosomal S6
kinase 2 (RSK2) is a direct upstream kinase able to phosphorylate
ATF4. RSK2 mutation has been found in the CofﬁneLowry Syn-
drome, an X-linked disorder characterized by skeletal anomalies
and mental retardation. RSK2 deﬁcient mice display a similar
phenotype as ATF4 mutant mice26,27. Interestingly, ATF4 also pro-
motes osteoclast differentiation and bone resorption via direct and
indirectmechanisms28,29. Further, ATF4may regulate differentiation
of osteochondral progenitors in an Ihh dependent mechanism30,31.
Based on these observations, we hypothesized that BMP-2
regulates ATF4 expression and activity in chondrocytes in a COX-
2 dependent manner. Our current study aimed to establish a mo-
lecular cascade linking these pathways. Our results show that BMP-
2 increases COX-2 expression via a classic ALK3eSmad1 pathway.
PGE2 induces ATF4 phosphorylation mainly through EP4 receptor
with downstream signaling involving ERK1/2-RSK2 activation.
Materials and methods
Cells
Primary mouse costosternal chondrocytes (PMCSC) were iso-
lated from the mice with different genetic backgrounds aspreviously described32,33. Brieﬂy, the rib cages including sterna
were dissected from 3-day-old pups. Soft tissue was removed after
serial incubation with pronase (Roche Laboratory, Nutley, NJ, USA,
2mg/ml in PBS) at 37C shaker for 45min and then in collagenase D
(Roche, 3 mg/ml in full medium) at 37C for 60 min. After thorough
wash, the rib cages were further digested with collagenase D in a
Petri dish for 5 h at 37C incubator. Then the cells were ﬁltered
through 40 mm mesh to remove tissue debris. After centrifuge, the
cell pellet was washed and re-suspended with Dulbecco’s Modiﬁed
Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS).
The C9 Tet-off cells were developed from mouse mesenchymal
C3H10T1/2 cells after transfection with the BMP-2 gene and anti-
biotic selection with hygromycin. C9 cells are under the control of
the inducible Tet-off system, e.g., no BMP-2 over-production in the
presence of doxycycline (1 mg/ml, Sigma, St. Louis, MO). After the
withdrawal of doxycycline, C9 cells overexpress BMP-2 and secrete
a large amount of BMP-234.
Rat chondrosarcoma cells (RCS) were used in some experiments
including reporter luciferase assay.
In some experiments, cells were pretreated with BMP-2 type I
receptor (BMPRI, ALK 2, 3, 6) inhibitor Dorsomorphin (10 nM,
Sigma) or a TAK1 inhibitor (5Z)-7-Oxozeaenol (10 nM, EMD Milli-
pore, Billerica, CA) for 1 h followed by other treatments.
Mice
The following genetically modiﬁed mice have been used in this
study: global knock-out (KO) mice: ALK6/ mice were from Dr.
Karen Lyons35, EP1/ mice from Dr. Matthew Breyer36, EP2/
mice from Dr. Richard Breyer37; conditional gene ﬂoxed mice:
ALK2fx/fx mice were from Dr. Vesa Kaartinen38; ALK3fx/fx from Dr.
Yuji Mishina39, Smad1fx/fx mice from NIH40; EP4fx/fx mice from Dr.
Matthew Breyer41, and TAK1fx/fx mice from Dr. Michael
Schneider42.
Luciferase assay
COX-2 gene promoter reporter was purchased from Panomics
(Santa Clara, CA) and transient transfection was performed in RCS
using Lipofectamine 2000 from Invitrogen (Grand Island, NY). Cell
culture medium containing Lipofectamine 2000 was removed after
12 h and BMP-2 (100 ng/ml, R&D Systems, Minneapolis, MN) was
added to culture medium for 48 h with vehicle as a control. Re-
porter luciferase assay was done in triplicate with a luminometer
(Opticom 1, Promega, Madison, WI).
Real time quantitative PCR (RT-PCR)
Total RNA was harvested using an RNeasy Mini kit (Qiagen,
Valencia, CA). Reverse transcription was done with a SuperScript
First Strand Synthesis System (Invitrogen). RT-PCR was per-
formed with QuantiTech SYBR Green PCR kit (Qiagen) in Rotor-
Gene Real-Time DNA ampliﬁcation system (Corbett Research,
New South Wales, Australia) using the COX-2 primers: forward:
50-AGAAGGAAATGGCTGCAGAA-30, reverse: 30-GCTCGGCTTCCAG-
TATTGAG-50; Atf4 primers: forward: 50-TCGATGCTCTGTTTC-
GAATG-30, reverse: 30-GGCAACCTGGTCGACTTTTA-50. The
expression levels of the genes of interest (GOI) were analyzed
with the software from Qiagen. For each GOI, a standard curve
was established and a value of each treatment group was ob-
tained. Similarly, a standard curve was established for b-actin
and its value in each group was calculated. RT-PCR was done in
quadruplicate and each GOI value was normalized by b-actin
values. The mean and SD were generated with software from
these normalized values.
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Prior to BMP-2 treatment, PMCSC were starved for 24 h in
serum-free medium. Then, cells were treated with BMP-2 (100 ng/
ml) for 12 h and supernatants were collected. PGE2 concentration
was measured using an enzyme immunoassay (EIA) kit from
Cayman Chemical (Ann Arbor, MI), and the results were repre-
sented as the means values from six wells and standard deviations.
Construction of EP4-V5 plasmid
The plasmid was constructed using the Gateway Technology
System (Invitrogen). Brieﬂy, mouse EP4 receptor cDNA was pro-
duced by PCR with high ﬁdelity polymerase (Invitrogen). A Gate-
way entry clone from an attB-ﬂanked PCR product was created
with a TOPO cloning reaction. Through an LR reaction, the product
was subcloned to the destination vector pcDNA3.2/V5-DEST. Af-
ter sequencing, the correct clone was ampliﬁed for future study.
Western blotting and immunoprecipitation (IP)
The nonprostanoid EP4 receptor agonist CP-734432 was ob-
tained from Pﬁzer Global Research and Development (Groton, CT).
For in vitro studies, it was used at a ﬁnal concentration of 106 M.
Cells were lysed with golden lysis buffer (20 mM Tris, 137mMNaCl,
5 mM Na2EDTA, 10% glycerol, 1% Triton X-100, 1 mM phenyl-
methylsulfonyl ﬂuoride, 1 mM aprotinin, 1 mM leupeptin, 1 mM
pepstatin A, 10 mM NaF, 1 mM Na3VO4, 1 mM EGTA, 1 mM tetra-
sodium PP1, and 100 mM P-glycerophosphate). Western blot was
performed with the invitrogen system. Chemiluminescence was
done with West Femto reagent (Thermo Fisher Scientiﬁc, Rockford,
IL). The following antibodies were used in the experiments: COX-2
(Cayman Chemicals), ATF4 and phospho-ATF4 (Abcam, Cambridge,
MA), phospho-ERK1/2 and phospho-RSK-2 (Cell Signaling Tech-
nology, Boston, MA). The experiments were usually repeated for
three times. After establishing the trends of protein expression, the
clear results with less variation were chosen and represented.
IP was performed using the Catch and Release Reversible IP System
(EMD Millipore). The protein was pulled down with V5 antibody
(Invitrogen) and GST antibody (Sigma) was used as antibody con-
trol. IP was performed using antibodies against phospho-EKR1/2
and RSK-2.
In vitro gene deletion
PMCSCwere isolated and cultured in DMEM containing 10% FBS.
After starvation for 24 h in serum-free medium, the cells were
infected with adenovirus (multiplicity of infection of 10) encoding
either Cre or GFP (Baylor Collage, TX, website: http://www.bcm.
edu/vector/instock-av) for 3 days. After recovering in the standard
culture medium containing 10% FBS for 2 days, these cells were
subjected to different treatments.
Immunohistochemistry (IHC)
The Day 7 fracture tibial callus samples harvested from wild
type (WT) and COX-2/ mice were ﬁxed, decalciﬁed and
embedded. Parafﬁn sections were cut and immunostained using an
avidin-biotin peroxidase detection system (Vector Labs, Burlin-
game, CA). After quenching endogenous peroxidase and blocking
non-speciﬁc signals, the sections were incubated overnight at 4C
with the primary antibody against phospho-ATF4 (1:100, Abcam).
The sections were thoroughly washed and then incubated with a
biotinylated secondary antibody (Vector) for 2 h at roomtemperature. Color reactions were developed with dia-
minobenzidine (DAB) as substrate (Vector).
Statistical analysis
The PASW software was used in this study. After testing the
homogeneity of variances, the log-transformed values were used
for analysis of variances (ANOVA). Following analysis of overall
group differences on the mean values at 0.05 alpha levels were
adjusted using the Turkey correction for multiple comparisons.
Results
BMP-2 increases COX-2 promoter activity and COX-2 protein
expression
RCSs were transiently transfected with the COX-2 promoter
construct for 12 h and then treated with BMP-2 for 48 h. Luciferase
assay showed that BMP-2 treatment increased COX-2 promoter
activity [Fig. 1(A)]. A time-course study was performed to examine
the effect of BMP-2 on COX-2 protein expression in PMCSC. BMP-2
treatment increased COX-2 protein levels at 6 h and the peak effect
occurred at 12 h [Fig. 1(B)]. The COX-2 protein levels remained
elevated in the BMP-2 treated cultures over the 48 h culture period.
Subsequent experiments were designed to determine the signaling
pathway through which BMP-2 stimulates COX-2 expression.
PMCSC were ﬁrst incubated with either BMPRI inhibitor or TAK1
inhibitor for 1 h and then treated with BMP-2 for 12 h. Treatment
with BMP-2 in control cultures caused approximately a 3-fold
upregulation of COX-2 mRNA expression. This induction in COX-2
was abolished when the cells were pretreated with the BMPRI in-
hibitor. In contrast, pre-treatment of the cell cultures with TAK1
inhibitor resulted in a normal induction of COX-2 expression by
BMP-2 [Fig.1(C)]. These ﬁndings suggest that BMP-2 regulates COX-
2 expression mainly through the classic Smad signaling pathway.
The effect of the endogenous BMP-2 on COX-2 expression was
examined using C9 Tet-off cells. These cells have normal levels of
BMP-2 expression in the presence of doxycycline, but have activa-
tion of a BMP-2 transgene upon the withdrawal of doxycycline and
thus over-expression of BMP-2. BMP-2 was increased 48 h after
removal of doxycycline compared to C9 cells maintained in doxy-
cycline containing medium. The cultures with over-expression of
endogenous BMP-2 also had upregulated COX-2 expression
[Fig. 1(D)].
BMP-2 regulates COX-2 expression in a classic ALK3-Smad pathway
PMCSC were isolated from Alk2fx/fx, Alk3fx/fx, and Alk6/ mice.
The ﬂoxed chondrocytes were infected with Ad-GFP or Ad-Cre for 3
days to induce Cre-mediated gene recombination. Then, PMCSC
were treated with BMP-2 for 48 h and protein samples were har-
vested. Western blotting analysis showed that the Alk2fx/fx PMCSC
infected with Ad-GFP were responsive to BMP-2 and had increased
COX-2 protein expression in BMP-2 treated cultures. Deletion of the
Alk2 gene in Ad-Cre treated cultures resulted in a slight increase in
the basal level of COX-2 protein, and the cells continued to respond
to BMP-2 with an increase in COX-2 expression [Fig. 2(A)]. Alk3
deﬁciency resulted in essentially a complete loss of the BMP-2
response of COX-2 induction [Fig. 2(B)]. Similar to the observa-
tions in Alk2 deﬁcient mice, The Alk6/ PMCSC had an elevated
basal level of COX-2 and continued to respond to BMP-2 with in-
duction of COX-2 expression [Fig. 2(C)]. Using a similar approach,
we have conﬁrmed that regulation of COX-2 by BMP-2 is mediated
through BMPR/Smad signaling pathway. PMCSC isolated from
Smad1fx/fx and Tak1fx/fx mice were infected with either Ad-GFP or
AB
COX-2
β-actin
BMP-2      - 50  100    - 50   100    - 50  100   - 50  100
(ng/ml)     
Hours              6               12                 24                 48
D
COX-2
β-actin
Doxycycline    +   - 48h
BMP-2
C RT-PCR (COX-2)
BMP-2       - +      - +      - +          
TAK1X - - +     +       - -
BMPRIX - - - - +     +
COX-2 luciferase assay
-DNA   pcDNA PGL4 COX-2  COX-2
BMP-2    - - - - +
* *
Fig. 1. Luciferase assay was performed in triplicate after transient transfection of human COX-2 gene promoter reporter construct to RCS. BMP-2 treatment for 48 h resulted in
approximately 2-fold increase of COX-2 luciferase activity (A). Western blotting analysis demonstrated that BMP-2 mediated COX-2 protein upregulation occurred at 6 h and peaked
at 12 h after treatment (B). PMCSC were pretreated with BMPRI or TAK1 inhibitor and followed by a BMP-2 treatment for 12 h. RT-PCR was performed in quadruplicate and the
results showed that TAK1 inhibitor did not have signiﬁcant effect on the BMP-2 induced COX-2 expression. In contrast, BMPR1 inhibitor almost completely abrogated BMP-2 effect
on COX-2 mRNA expression (C). TAK1x: TAK1 inhibitor, BMPRIx inhibitor, *signiﬁcant difference between lane 1 and 2 (P ¼ 0.01), **signiﬁcant difference between lane 3 and 4
(P ¼ 0.03). The effect of endogenous BMP-2 on COX-2 expressionwas investigated in Tet-off C9 cells. Western blotting analysis showed that 48 h after removal of doxycycline, BMP-2
expression was upregulated with a subsequent increase in COX-2 protein expression (D).
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Fig. 2. Western blot analysis revealed that the BMP-2 mediated COX-2 induction was partially preserved in Alk2fx/fx PMCSC infected with Ad-Cre (A). In contrast, In vitro deletion of
Alk3 by infecting Alk3fx/fx PMCSC with Ad-Cre resulted in a signiﬁcant loss of BMP-2 responsiveness regarding COX-2 expression (B). The ALK6/ PMCSC showed a similar response
to BMP-2 as WT cells regarding COX-2 protein induction (C). In vitro deletion of Smad1 in PMCSC signiﬁcantly abrogated the BMP-2 effect on COX-2 expression (D). In contrast,
deletion of Tak1 by infecting the Tak1fx/fx PMCSC with Ad-Cre had a minimal effect on the BMP-2 mediated COX-2 expression (E). Veh: vehicle control.
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2 induction by BMP-2 [Fig. 2(D)]. In contrast, deletion of the Tak1
gene did not alter the stimulatory effect of BMP-2 on COX-2
expression [Fig. 2(E)]. These ﬁndings suggest that BMP-2 regu-
lates COX-2 expression primarily through the classic ALK3eSmad1
signaling pathway.BMP-2 increases PGE-2 production
PGE-2 EIA revealed that BMP-2 treatment resulted in an
enhanced production of PGE2 in mouse articular chondrocytes.
PGE2 concentration was measured 12 h after treatment and rep-
resented as the mean and standard deviation (BMP-2 treatment:
487.08  57.99; vehicle control: 211.07  31.16).BMP-2 induces ATF4 phosphorylation through COX-2/PGE2
signaling
As PGE2, the major metabolite of COX-2, has been shown to
stimulate ATF4 phosphorylation in prostate cancer cells24, we
subsequently conducted experiments to determine whether PGE2
regulates ATF4 phosphorylation in chondrocytes. Treatment of
PMCSC with PGE2 did not result in changes in Atf4 mRNA expres-
sion (data not shown). However, PGE2 strongly stimulated ATF4
phosphorylation after 2 and 4 h of treatment [Fig. 3(A)]. The Tet-off
C9 cells were used to examine if endogenous BMP-2 regulates ATF4
phosphorylation. Doxycycline was removed from culture medium
and Western blotting analysis was performed with the antibodies
against phospho-ATF4, total ATF4, and BMP-2. Over-expression of
BMP-2 was detected 48 h after the withdrawal of doxycycline, at
which point increased expression of ATF4 protein and enhanced
ATF4 phosphorylation was observed [Fig. 3(B)]. To determine if
BMP-2 regulates ATF4 phosphorylation in a COX-2 dependentA pATF4
β-actin
PGE-2          - +      - +
Hours             2            4
tATF4
B Tet-Off C9 Cells
tATF4
β-actin
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Fig. 3. PMCSC isolated fromWT mice were treated with PGE2 (106 M) for 2 or 4 h and West
endogenous BMP-2 on ATF4 phosphorylation was examined in the Tef-off C9 cells. The resu
slight increase of total ATF4 protein. ATF4 phosphorylation then became evident (B). PMC
analysis was performed with an antibody for phospho-ATF4. While BMP-2 induced ATF4 p
fracture callus samples from COX-2/ mice showed a much weaker immunoreactivity to pmechanism, PMCSC were isolated from WT and COX-2/ mice.
While BMP-2 induced ATF4 phosphorylation in WT PMCSC, the
induction of ATF4 phosphorylation was absent in COX-2/ PMCSC
[Fig. 3(C)]. Consistent with these ﬁndings, callus samples from tibia
fracture of COX-2/ mice harvested at Day 7 post-surgery showed
much weaker immunostaining to phospho-ATF4 compared to the
staining present in WT mice [Fig. 3(D)].PGE2 mediates ATF4 phosphorylation through EP4 receptor
As COX-2ePGE2 mediated signaling is necessary for ATF4
phosphorylation, experiments were performed to examine the
relative importance of the EP receptors in the PMCSC population.
PMCSC were isolated from EP1/, EP2/ and EP4fx/fx mice. PMCSC
from EP4fx/fx mice underwent Cre recombination in vitro following
infection with Ad-Cre. Western blot analysis was performed using
cell lysates extracted from cultures with 2-h treatment with PGE2.
PGE2 stimulated ATF4 phosphorylation in EP1/ PMCSC [Fig. 4(A)],
indicating that the EP1 receptor is not involved in the phosphory-
lation ATF4. EP2/ PMCSC had an elevated basal level of phospho-
ATF4. In contrast to EP1/ PMCSC, no increase in ATF4 phosphor-
ylation occurred following PGE2 treatment in EP2/ PMCSC cul-
tures [Fig. 4(B)]. PMCSC isolated from EP4fx/fx mice were infected
with Ad-Cre or Ad-GFP. Deletion of the EP4 gene reduced the basal
level of phospho-ATF4 and blocked the induction of ATF4 phos-
phorylation by PGE2 [Fig. 4(C)].EP4, ERK1/2 and RSK2 form a protein complex
ATF4 is a member of the cAMP response element binding pro-
teins (CREB) and is phosphorylated by protein kinase A (PKA)
signaling. EP2 and EP4 both are known activators of the PKA
signaling pathway. In addition, ATF4 phosphorylation is mediatedC
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ern blotting analysis showed that PGE2 induced ATF4 phosphorylation (A). The effect of
lts indicated that BMP-2 was overexpressed 48 h after doxycycline withdrawal with a
SC from both WT and COX-2/ mice were treated with BMP-2 and Western blotting
hosphorylation in WT PMCSC, its effect was largely lost in COX-2/ PMCSC (C). Day 7
hospho-ATF4 than that in WT samples (D).
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Fig. 4. The PGE2 effect on the phosphorylation of ATF4 was well-reserved in the EP1/ PMCSC (A). Although the basal level of phospho-ATF4 was slightly higher in the EP2/
PMCSC, such cells lost their responsiveness to the PGE2 regarding ATF4 phosphorylation (B). In vitro deletion of EP4 receptor by infecting EP4fx/fx PMCSC with Ad-Cre signiﬁcantly
abrogated the PGE2 effect on ATF4 phosphorylation (C).
T.-F. Li et al. / Osteoarthritis and Cartilage 22 (2014) 481e489486by ERK1/2eRSK2 signaling. We performed further experiments to
determine whether EP4 activates ERK1/2 signaling in PMCSC.
Treatment of PGE2 for 30 min resulted in a robust stimulation of
ERK1/2 phosphorylation, and EP4 agonist, less a lesser extent, also
induced ERK1/2 phosphorylation [Fig. 5(A)]. We then constructed a
plasmid consisting of EP4 receptor fused to the V5 tag and trans-
fected this plasmid into RCS cells. The cells were treated with PGE2
for 1 h and the cell lysates were subjected to IP using either GST or
V5 antibody, followed by immunoblotting with antibodies against
phospho-ERK1/2 and phospho-RSK2. Our results suggested that
EP4, phospho-ERK1/2 and phospho-RSK2 formed a proteinepro-
tein complex [Fig. 5(B)], consistent with the regulation of ATF4
phosphorylation. Such complex formationwas not detectible in the
lysates from untreated cells.A
Tr
IP
IB
IBB
pERK1/2
tERK1/2
Veh EP4*  PGE2
Fig. 5. The lysates from the PMCSC treated with PGE2 or EP4 agonist were subjected to West
agonist induced the phosphorylation of ERK1/2 (A). RCS cells were transfected with either
noprecipitated with the antibodies for either V5 or GST. Western blotting was performed wit
upon PGE2 treatment, EP4 formed the complex with both phospho-ERK1/2 and phospho-RS
Veh: vehicle control, EV: empty vector.Discussion
Previous studies have established that both BMP-2 and COX-2
gene expressions are important signals in bone regeneration
(4,13). The current study shows that COX-2 expression in PMCSC
is regulated by BMP-2 signaling. Pharmacologic and genetic ap-
proaches were subsequently used to deﬁne the signaling path-
ways involved in the induction of COX-2 by BMP-2, and to
examine subsequent signaling events downstream of COX-2 and
its major metabolite PGE2. The experiments establish that BMP-2
induces COX-2 through a pathway that involves ALK3/Smad1
signaling with a subsequent increased PGE2 production. We
further establish that induction of ATF4 phosphorylation by BMP-
2 is dependent on COX-2 expression and is mediated by a PGE2ansfection             EV                 V5-EP4
 antibody         GST     V5        GST      V5
: pRSK-2
: pERK1/2
PGE-2
ern blotting analysis with antibodies for total and phospho-ERK1/2. Both PGE2 and EP4
V5-tagged EP4 receptor (V5-EP4) or the emptor vector (EV) and lysates were immu-
h the antibodies against phospho-ERK1/2 and phospho-RSK-2. The result suggested that
K2 (B). Such complex formation was not observed in untreated cells. EP4*: EP4 agonist,
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scription factor in chondrocytes. Since one of the mechanisms
for ATF4 phosphorylation involves RSK2/ERK1/2 signaling, we
examined the potential for EP4 to activate this pathway in
chondrocytes. We demonstrated that PGE2 and an EP4 agonist
stimulate ERK1/2 phosphorylation. Furthermore, the IP experi-
ments established that the EP4 receptor co-precipitates with
RSK2 and ERK1/2. Altogether the experiments show that BMP-2
stimulates important regulatory pathways in chondrocytes
through the induction of COX-2 and subsequent downstream
signaling events.
Both BMP-2 and COX-2/PGE2 are critical factors in the early
responses to bone injury and are required for normal bone regen-
eration (4,13). BMP-2 has been shown to be expressed in early
fracture repair in mesenchyme and in immature chondrocytes.
Because global deletion of BMP-2 results in early embryonic death,
the effects of BMP-2 deletion in bone regeneration has been
examined in mice with constitutive gene deletion using a Prx1-Cre
that results in loss of gene expression in limb mesenchyme derived
cell populations. Fractures in mice with constitutive deletion of
BMP-2 have marked inhibition of fracture healing with reduced
proliferation of periosteal cells along the bone surface, minimal
accumulation of callus tissues, and delayed differentiation of
cartilage and bone43. In contrast, deletion of BMP-4 has minimal
effects44, suggesting that BMP-2 is particularly important in bone
regeneration and that other factors do not compensate for absence
of BMP-2.
The COX-2 gene is also expressed early in fractures and its
expression corresponds primarily with the endochondral phase
of bone repair. Peak COX-2 expression has been observed at the
time when an immature cartilage callus has developed repair. In
situ hybridization of murine fracture callus has shown expression
of COX-2 primarily in chondro-progenitors that co-express col2a1
and in immature chondrocytes, with reduced expression occur-
ring as chondrocytes mature. Prior work in our laboratory and by
others has shown that COX-2 is critical for the early events in
fracture healing mature13,45,46. The fracture healing phenotype
observed with deletion of COX-2 is similar, although not as se-
vere, as that observed with conditional deletion of the BMP-2.
COX-2 gene deletion results in reduced proliferation of the
periosteal cell population, decreased accumulation of fracture
callus, and delayed differentiation of bone and cartilage. The
similarities, but less severe phenotype observed in COX-2
compared to BMP-2 gene deletion suggests that these signals
may be linked. The current ﬁndings demonstrate that BMP-2
regulates the expression of COX-2 in chondrocytes and that
COX-2 is involved in the activation of important signals in
cartilage.
Classic BMP signaling starts with the ligand binding to the type
II receptor with subsequent recruitment and phosphorylation of
the type I receptors (ALK2, 3, 6). The activated type I BMP receptor
phosphorylates the receptor associated Smad3 (Smad1, 5, 8). In this
study, we took advantage of the genetically modiﬁed mice to
establish the pathway through which BMP-2 regulates COX-2
expression. We ﬁrst demonstrate that the classic ALK3eSmad1
pathway is the major transducer of the BMP-2 effect on COX-2
expression. In addition to classic Smad pathway, many non-Smad
pathways are activated following BMP-2 treatment. We focused
on the TAK1/MAPK pathway because this pathway has been stud-
ied intensively and mounting evidence suggests a pivotal role of
this pathway in chondrocyte differentiation. Our recent publication
shows an interdependent relationship between TGF-b-TbRI-Smad3
signaling and TAK1eMAPK pathway11. The report from Dr.
Glimcher’s group suggests an essential role of TAK1 in mediating
BMP-2 signaling in chondrocytes9. We thus focused on TAK1/MAPKsignaling in the BMP-2 mediated COX-2 expression in chon-
drocytes, and compared the effect of this non-Smad pathway to the
classic Smad pathway. Our results for the ﬁrst time establish that
classic ALK3-Smad1 pathway plays a major role in the BMP-2 effect
on COX-2.
PGE2 is a major end product of COX-2 and it takes effect through
its cell surface receptors from EP1 to EP4. While EP1 is a negative
regulator of fracture healing21, both EP2 and EP4 signaling accel-
erate skeletal repair19,20. These two receptors belong to the
G-protein coupled receptor family able to activate the cAMP/PKA
signaling. In addition to EP2/4ePKA signaling, other pathways may
also mediate PGE2 effect. EP4 is unique because it has a long
intracellular domain. Upon ligand binding, EP4 can be internalized
to cytoplasm, where it binds to and interacts with different mole-
cules transmitting different PGE2 effect. Previous studies have
demonstrated that PGE2 activates ERK1/2 MAPK pathway through
EP4, and ERK1/2 can phosphorylate RSK2. In cancer cells, PGE2
induces ATF4 phosphorylation. RSK2 is a direct upstream kinase for
ATF4 phosphorylation, and its mutation in human results in
insufﬁcient ATF4 phosphorylation, which causes the CofﬁneLowry
Syndrome characterized by mental retardation and skeletal
anomalies. Not surprisingly, RSK2 mutant mice exhibit a bone loss
phenotype.
Based on these observations, we postulated that modulation of
RSK2 activity may partially mimic BMP-2 effect on cartilage and
bone. Our current study aimed to establish a molecular reaction
cascade linking COX-2 upregulation, PGE2 over-production, and
ATF4 phosphorylation. Our observations made in genetically
engineered mice suggest that both EP2 and EP4 receptors are
involved in the PGE2 mediated ATF4 phosphorylation. We
focused on EP4 because it has a unique molecular structure and
its interaction with other molecules in cytoplasm may transduce
different PGE2 effect. Our IP experiment indicates a complex
formation of EP4-pERK1/2-pRSK2. Such complex was not detec-
tible in the absence of PGE2. Based on the observations from
others and our own, we hypothesized that PGE2 may induce ATF4
phosphorylation via the EP2/4-ERK1/2-RSK2 axis. Noteworthy,
different phosphorylation sites in ATF4 molecule may have
different effect on ATF4 activity/function. Thus, more studies
are needed to generate more detailed information of ATF4
phosphorylation.
Although our current study did not focus on chondrocyte dif-
ferentiation through these molecular cascades, accumulating data
suggest that ATF4 work either alone or together with other tran-
scription factors to regulate differentiation of osteochondral pro-
genitor cells. Recent ﬁndings suggest that ATF4 takes its effect
through Ihh, an important molecule driving chondrocyte differen-
tiation30,31. Prior work in our laboratory showed reduced expres-
sion of Ihh in fracture callus of COX-2/ mice. Treatment of these
mice with an EP4 agonist markedly increased Ihh expression18. In
this study, we demonstrate reduced expression of phospho-ATF4 in
fracture callus of COX-2/ mice. Together, these observations
further support a signaling cascade linking BMP-2-COX-2-PGE2-
EP4-RSK2-ATF4, with possible involvement of Ihh. Our future
work will focus on the relationship between the phosphorylation
status of ATF4 and some skeletal diseases.
Conclusions
BMP-2 upregulates COX-2 expression via the classic Smad
signaling pathway. In addition, BMP-2 regulates ATF4 phosphory-
lation in a COX-2 dependent manner. Further, BMP-2 increases
PGE2 production and PGE2 induces ATF4 phosphorylation pri-
marily through EP2/4 receptor with the downstream signaling
events involving the activation of ERK1/2 and RSK2.
T.-F. Li et al. / Osteoarthritis and Cartilage 22 (2014) 481e489488Author contribution
TFL: the conception and design, acquisition, analysis and inter-
pretation of data, manuscript preparation, and ﬁnal approval of the
version to be submitted. KY: the study design, acquisition and
analysis of data. GY: the acquisition, analysis and interpretation of
data. TS: the acquisition, analysis and interpretation of data. TM:
the acquisition, analysis and interpretation of data. JHJ: the acqui-
sition, analysis and interpretation of data, manuscript preparation.
WS: the conception and design, and critical revision of the manu-
script. XZ: The conception and design. GX: preparation and critical
revision of the manuscript. YTK: the conception and design, and
critical revision of the manuscript.
DC: the conception and design, critical revision of the manu-
script. RJO: obtaining funding, the conception and design, inter-
pretation of data, manuscript preparation, and ﬁnal approval of the
version to be submitted.
Conﬂict of interest
No author in this study has received ﬁnancial support of any form.
None of them has a potential of conﬂict of interest.
Role of funding source
The sponsor had not involved in any process of the current study,
e.g., the study design, the collection, analysis, and interpretation of
data, manuscript preparation and journal submission.
Acknowledgments
This study was supported an NIH grant 5R01AR048681. We
thank Ming Xue for her technical assistance, and Dr Yinglin Xia and
Dr Shaoping Wu for their assistance with statistical analysis.
References
1. Cao X, Chen D. The BMP signaling and in vivo bone formation.
Gene 2005;357(1):1e8.
2. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic
protein receptors and signal transduction. J Biochem 2010;
147(1):35e51.
3. Lad SP, Nathan JK, Boakye M. Trends in the use of bone
morphogenetic protein as a substitute to autologous iliac crest
bone grafting for spinal fusion procedures in the United States.
Spine 2011;36(4):E274e81.
4. Even J, Eskander M, Kang J. Bone morphogenetic protein in
spine surgery: current and future uses. J Am Acad Orthop Surg
2012;20(9):547e52.
5. Chrastil J, Patel AA. Complications associated with posterior
and transforaminal lumbar interbody fusion. J Am Acad Orthop
Surg 2012;20(5):283e91.
6. Argintar E, Edwards S, Delahay J. Bone morphogenetic proteins
in orthopaedic trauma surgery. Injury 2011;42(8):730e4.
7. Lee KB, Taghavi CE, Murray SS, Song KJ, Keorochana G,
Wang JC. BMP induced inﬂammation. J Orthop Res 2012;
30(12):1985e94.
8. Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T. BMP-2-
induced apoptosis is mediated by activation of the TAK1-p38
kinase pathway that is negatively regulated by Smad6. J Biol
Chem 2000;275(23):17647e52.
9. Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B,
et al. TAK1 is an essential regulator of BMP signalling in
cartilage. EMBO J 2009;28(14):2028e41.
10. Gunnell LM, Jonason JH, Loiselle AE, Kohn A, Schwarz EM,
Hilton MJ, et al. TAK1 regulates cartilage and jointdevelopment via the MAPK and BMP signaling pathways.
J Bone Min Res 2010;25(8):1784e97.
11. Li TF, Gao L, Sheu TJ, Sampson ER, Flick LM, Konttinen YT, et al.
Aberrant hypertrophy in Smad3-deﬁcient murine chon-
drocytes is rescued by restoring transforming growth factor
beta-activated kinase 1/activating transcription factor 2
signaling: a potential clinical implication for osteoarthritis.
Arthritis Rheum 2010;62(8):2359e69.
12. Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky OS,
Adams DJ, et al. Bone morphogenetic protein 2 induces cyclo-
oxygenase 2 in osteoblasts via a Cbfal binding site: role in
effects of bone morphogenetic protein 2 in vitro and in vivo.
J Bone Min Res 2002;17(8):1430e40.
13. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN,
O’Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell
differentiation into the osteoblast lineage and is critically
involved in bone repair. J Clin Invest 2002;109(11):1405e15.
14. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol
Chem 2007;282(16):11613e7.
15. Li TF, Zuscik MJ, Ionescu AM, Zhang X, Rosier RN, Schwarz EM,
et al. PGE2 inhibits chondrocyte differentiation through PKA
and PKC signaling. Exp Cell Res 2004;300(1):159e69.
16. Arikawa T, Omura K, Morita I. Regulation of bone morphoge-
netic protein-2 expression by endogenous prostaglandin E2 in
human mesenchymal stem cells. J Cell Physiol 2004;200(3):
400e6.
17. Welting TJ, Caron MM, Emans PJ, Janssen MP, Sanen K,
Coolsen MM, et al. Inhibition of cyclooxygenase-2 impacts
chondrocyte hypertrophic differentiation during endochon-
dral ossiﬁcation. Eur Cell Mater 2011;22:420e36.
18. Xie C, Liang B, Xue M, Lin AS, Loiselle A, Schwarz EM, et al.
Rescue of impaired fracture healing in COX-2/ mice via
activation of prostaglandin E2 receptor subtype 4. Am J Pathol
2009;175(2):772e85.
19. Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B,
Grasser WA, et al. An EP2 receptor-selective prostaglandin E2
agonist induces bone healing. Proc Natl Acad Sci USA
2003;100(11):6736e40.
20. Tanaka M, Sakai A, Uchida S, Tanaka S, Nagashima M,
Katayama T, et al. Prostaglandin E2 receptor (EP4) selective
agonist (ONO-4819.CD) accelerates bone repair of femoral
cortex after drill-hole injury associated with local upregulation
of bone turnover in mature rats. Bone 2004;34(6):940e8.
21. Zhang M, Ho HC, Sheu TJ, Breyer MD, Flick LM, Jonason JH,
et al. EP1 (/) mice have enhanced osteoblast differentiation
and accelerated fracture repair. J Bone Min Res 2011;26(4):
792e802.
22. Desai S, April H, Nwaneshiudu C, Ashby B. Comparison of
agonist-induced internalization of the human EP2 and EP4
prostaglandin receptors: role of the carboxyl terminus in EP4
receptor sequestration. Mol Pharmacol 2000;58(6):1279e86.
23. Fujino H, Xu W, Regan JW. Prostaglandin E2 induced func-
tional expression of early growth response factor-1 by EP4, but
not EP2, prostanoid receptors via the phosphatidylinositol 3-
kinase and extracellular signal-regulated kinases. J Biol Chem
2003;278(14):12151e6.
24. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin
E2 regulates tumor angiogenesis in prostate cancer. Cancer Res
2008;68(19):7750e9.
25. Romeo Y, Zhang X, Roux PP. Regulation and function of the
RSK family of protein kinases. Biochem J 2012;441(2):553e69.
26. Sassone-Corsi P, Mizzen CA, Cheung P, Crosio C, Monaco L,
Jacquot S, et al. Requirement of Rsk-2 for epidermal growth
factor-activated phosphorylation of histone H3. Science
1999;285(5429):886e91.
T.-F. Li et al. / Osteoarthritis and Cartilage 22 (2014) 481e489 48927. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T,
et al. ATF4 is a substrate of RSK2 and an essential regulator of
osteoblast biology; implication for CofﬁneLowry Syndrome.
Cell 2004;117(3):387e98.
28. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al.
Leptin regulation of bone resorption by the sympathetic ner-
vous system and CART. Nature 2005;434(7032):514e20.
29. Cao H, Yu S, Yao Z, Galson DL, Jiang Y, Zhang X, et al. Activating
transcription factor 4 regulates osteoclast differentiation in
mice. J Clin Invest 2010;120(8):2755e66.
30. Wang W, Lian N, Li L, Moss HE, Wang W, Perrien DS, et al. Atf4
regulates chondrocyte proliferation and differentiation during
endochondral ossiﬁcation by activating Ihh transcription.
Development 2009;136(24):4143e53.
31. Wang W, Lian N, Ma Y, Li L, Gallant RC, Elefteriou F, et al.
Chondrocytic Atf4 regulates osteoblast differentiation and
function via Ihh. Development 2012;139(3):601e11.
32. Li TF, Darowish M, Zuscik MJ, Chen D, Schwarz EM, Rosier RN,
et al. Smad3-deﬁcient chondrocytes have enhanced BMP
signaling and accelerated differentiation. J Bone Min Res
2006;21(1):4e16.
33. Li TF, Chen D, Wu Q, Chen M, Sheu TJ, Schwarz EM, et al.
Transforming growth factor-beta stimulates cyclin D1
expression through activation of beta-catenin signaling in
chondrocytes. J Biol Chem 2006;281(30):21296e304.
34. Moutsatsos IK, Turgeman G, Zhou S, Kurkalli BG, Pelled G,
Tzur L, et al. Exogenously regulated stem cell-mediated
gene therapy for bone regeneration. Mol Ther 2001;3(4):
449e61.
35. Yi SE, Daluiski A, Pederson R, Rosen V, Lyons KM. The type I
BMP receptor BMPRIB is required for chondrogenesis in the
mouse limb. Development 2000;127(3):621e30.
36. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, et al. Antihyper-
tensive effects of selective prostaglandin E2 receptor subtype 1
targeting. J Clin Invest 2007;117(9):2496e505.37. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD,
et al. Salt-sensitive hypertension and reduced fertility in mice
lacking the prostaglandin EP2 receptor. Nat Med 1999;5(2):
217e20.
38. Dudas M, Sridurongrit S, Nagy A, Okazaki K, Kaartinen V.
Craniofacial defects in mice lacking BMP type I receptor Alk2
in neural crest cells. Mech Dev 2004;121(2):173e82.
39. Mishina Y, Hanks MC, Miura S, Tallquist MD, Behringer RR.
Generation of Bmpr/Alk3 conditional knockout mice. Genesis
2002;32(2):69e72.
40. Huang S, Tang B, Usoskin D, Lechleider RJ, Jamin SP, Li C, et al.
Conditional knockout of the Smad1 gene. Genesis 2002;32(2):
76e9.
41. Schneider A, Guan Y, Zhang Y, Magnuson MA, Pettepher C,
Loftin CD, et al. Generation of a conditional allele of the mouse
prostaglandin EP4 receptor. Genesis 2004;40(1):7e14.
42. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, et al.
A pivotal role for endogenous TGF-beta-activated kinase-1 in
the LKB1/AMP-activated protein kinase energy-sensor
pathway. Proc Natl Acad Sci USA 2006;103(46):17378e83.
43. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S,
Gerstenfeld L, et al. BMP-2 activity, although dispensable for
bone formation, is required for the initiation of fracture heal-
ing. Nat Genet 2006;38(12):1424e9.
44. Tsuji K, Cox K, Bandyopadhyay A, Harfe BD, Tabin CJ, Rosen V.
BMP4 is dispensable for skeletogenesis and fracture-healing in
the limb. J Bone Jt Surg Am 2008;90(Suppl 1):14e8.
45. Lau KH, Kothari V, Das A, Zhang XB, Baylink DJ. Cellular and
molecular mechanisms of accelerated fracture healing by COX-
2 gene therapy: studies in a mouse model of multiple frac-
tures. Bone 2013;53:369e81.
46. Naik AA, Xie C, Zuscik MJ, Kingsley P, Schwarz EM, Awad H,
et al. Reduced COX-2 expression in aged mice is associated
with impaired fracture healing. J Bone Min Res 2009;24(2):
251e64.
